Information:
Fel:
ID
45884
Beskrivning
Principal Investigator: Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000980 Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.
Länk
Nyckelord
Versioner (1)
- 2023-11-18 2023-11-18 - Simon Heim
Rättsinnehavare
Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Uppladdad den
18 november 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000980 PD-1 Blockade in Non-Small Cell Lung Cancer
The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- This subject sample mapping data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
Similar models
The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and affection status for case control status of the subject. All subjects are patients with non-small cell lung cancer.
- This subject sample mapping data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This sample attributes table contains de-identified sample ID, body site where sample was collected, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage, type of tumor treatment, and names of the center which conducted genotyping and sequencing.
- This subject phenotype table contains de-identified Subject ID, patient's cohort in current study, tumor histology, age, sex, smoking status and pack years, PD-L1 protein expression, prior courses of cytotoxic chemotherapy, pembrolizumab dose and administration, progression free survival, best overall response to pembrolizumab, durable clinical benefit and molecular smoking signature.
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
SUBJECT_ID
Item
Subject ID
string
C2348585 (UMLS CUI [1,1])
Item
Consent group as determined by DAC
text
C0021430 (UMLS CUI [1,1])
C0441833 (UMLS CUI [1,2])
C0441833 (UMLS CUI [1,2])
CL Item
Health/Medical/Biomedical (PUB, NPU) (HMB-PUB-NPU) (1)
SUBJECT_SOURCE
Item
Source repository where subjects originate
string
C3847505 (UMLS CUI [1,1])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
SOURCE_SUBJECT_ID
Item
Subject ID used in the Source Repository
string
C2348585 (UMLS CUI [1,1])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])
Item
Case control status of the subject. All subjects are patients with non-small cell lung cancer.
text
C3274646 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
C0681850 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
Code List
Case control status of the subject. All subjects are patients with non-small cell lung cancer.
CL Item
Control (1)
C3274648 (UMLS CUI [1,1])
CL Item
Case (2)
C3274647 (UMLS CUI [1,1])
CL Item
Other (3)